当前位置:循环首页>正文

[WCC2010]PPARs与RASS之间的交互应答—— Prof. Eckel专访

作者:国际循环网   日期:2010/7/2 13:04:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

<International Circulation>: Combination therapy may be an important concept in developing more effective strategies to treat and prevent atherosclerosis and coronary heart disease. Combination therapy with statins, PPARS (peroxisome proliferators-activated receptor agonists), and RAAS (renin-angiotensin-aldosterone system) blockers demonstrate additive beneficial effects. What is the current thinking on the relationship between PPARs and RAAS as presented at this meeting?

    <International Circulation>: Combination therapy may be an important concept in developing more effective strategies to treat and prevent atherosclerosis and coronary heart disease. Combination therapy with statins, PPARS (peroxisome proliferators-activated receptor agonists), and RAAS (renin-angiotensin-aldosterone system) blockers demonstrate additive beneficial effects. What is the current thinking on the relationship between PPARs and RAAS as presented at this meeting?

    Prof. Eckel: The important place to start is that the PPARs are a different class of compounds. It is just not simply PPARs but there are agents that have PPAR-alpha agonistic properties, those with –gamma agonistic properties and a newer class, the PPAR-delta agonists. These all modify metabolism in a somewhat different way. The interesting thing about the PPARs is that all have anti-inflammatory effects. That is where the idea of cross-talk with the RAAS compounds makes some sense. The question arises, because we have no clinical trials where the intent of the study was to examine these two classes of drugs head-to-head, whether the anti-inflammatory effects of the PPARs are additive or redundant with those of the RAAS inhibitors? Renin inhibitors, ACE inhibitors, and the ARB blockers, all modify inflammation in a favorable way, perhaps better characterized for the ACE inhibitors and the ARBs than the renin inhibitors. Never-the-less, the types of molecules that the renin-angiotensin-aldosterone system modifies are the same types of molecules that the PPARs do. They could be additive or even synergistic, but alternatively together they could add no additional value.

    The PPAR-alpha agonists are mostly lipid-modifying agents, whereas the PPAR-gamma agents are important in glucose metabolism and the treatment of diabetes. There is a small amount of overlap between the –alpha and –gamma functionally but not much. The PPAR-delta group seem to be more involved in energy balance and maybe also important in modifying body weight favorably. These various types of agonists in the PPAR system need to be distinguished one from the other in terms of their indications their interaction with the RAAS.

[1]  [2]  [3]  下一页

版面编辑:沈会会  责任编辑:其他


PPARsRASS

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2020 www.icirculation.com All Rights Reserved